Drug Combination Details
| General Information of the Combination (ID: C16256) | |||||
|---|---|---|---|---|---|
| Name | Apigenin NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
|
Discovery agent
[ICD-11: N.A.]
|
Investigative | [3] | |||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| Down-regulation | Loss of mitochondrial membrane potential | |||||
| In-vitro Model | SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | ||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | SK-Hep-1 cells (5*106 cells per mice) were suspended in 100 L of serum-free RPMI-1640 medium, then subcutaneously injected into the left flank of nude mice (Male, 4-6 weeks old). | |||||
| Experimental
Result(s) |
Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | PRKAA1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 15 | CVCL_0292 | Colon adenocarcinoma | Homo sapiens | ||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The dual-drug liposomes demonstrated enhanced inhibition of angiogenesis, better reduction in cell proliferation and increased apoptotic potential. Cell signaling studies indicating a significant upregulation of pAMPK and activity against downstream targets by dual drug liposomes. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-453 | CVCL_0418 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPX1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | 200 uL tumor cell suspensions, containing 2*106 Ehrlich ascites carcinoma cells, were subcutaneously injected into the right thigh of the hind limb of each mouse. | |||||
| Experimental
Result(s) |
The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice. | |||||
